Fatma A. Hapa

Izmir, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Anti-IL-17 therapy in people living with HIV who have cutaneous psoriasis: A four-patient case series.

Anti-IL-17 therapy in people living with HIV who have cutaneous psoriasis: A four-patient case series.

Journal: International journal of STD & AIDS

Published: September 03, 2026

Long-term Clinical Efficacy, Safety, and Drug Survival of Ixekizumab for Patients with Psoriasis in a Real-life Setting.

Long-term Clinical Efficacy, Safety, and Drug Survival of Ixekizumab for Patients with Psoriasis in a Real-life Setting.

Journal: Acta dermatovenerologica Croatica : ADC

Published: November 03, 2025

Predictive factors for early super response to bimekizumab in 341 patients with psoriasis-a 24-week short-term multicenter real-life experience.

Predictive factors for early super response to bimekizumab in 341 patients with psoriasis-a 24-week short-term multicenter real-life experience.

Journal: The Journal of dermatological treatment

Published: October 01, 2025

Secukinumab Treatment in Patients with Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study.

Secukinumab Treatment in Patients with Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study.

Journal: Dermatology practical & conceptual

Published: October 26, 2024

A Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Phase 2 Study Evaluating the Efficacy and Safety of GN-037 Cream in Patients with Mild-to-Moderate Plaque Psoriasis.

A Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Phase 2 Study Evaluating the Efficacy and Safety of GN-037 Cream in Patients with Mild-to-Moderate Plaque Psoriasis.

Journal: Dermatology and therapy

Published: September 13, 2024

Evaluation of serial QuantiFERON-TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti-IL-17 treatment (secukinumab and ixekizumab): Real-world data from a tuberculosis-endemic country.

Evaluation of serial QuantiFERON-TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti-IL-17 treatment (secukinumab and ixekizumab): Real-world data from a tuberculosis-endemic country.

Journal: The Australasian journal of dermatology

Published: January 05, 2024

Long-term efficacy, safety, and drug survival of secukinumab in patients with psoriasis in Turkey: a retrospective analysis of real-world experience.

Long-term efficacy, safety, and drug survival of secukinumab in patients with psoriasis in Turkey: a retrospective analysis of real-world experience.

Journal: Postepy dermatologii i alergologii

Published: June 15, 2023

Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting.

Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting.

Journal: Journal of cosmetic dermatology

Published: April 18, 2022

Is dupilumab effective in adult-onset atopic dermatitis: Real-life experience of 16 patients.

Is dupilumab effective in adult-onset atopic dermatitis: Real-life experience of 16 patients.

Journal: Journal of cosmetic dermatology

Published: January 16, 2022

A real life experience with ustekinumab: The effectiveness of 45 mg on patients greater than 80 kg but lower than 100 kg.

A real life experience with ustekinumab: The effectiveness of 45 mg on patients greater than 80 kg but lower than 100 kg.

Journal: Dermatologic therapy

Published: November 09, 2021

Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey.

Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey.

Journal: The Journal of dermatological treatment

Published: October 19, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026